BioMarin Pharmaceuticalvs.Incyte
BMRN vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte is about 2.2× larger than BioMarin Pharmaceutical by market cap; Incyte trades at the lower P/E (14.2 vs 144.9); year to date, Incyte leads (+14.2% vs −7.6%).
Side by side
| BMRN | INCY | |
|---|---|---|
| Market cap | $10.6B | $22.9B |
| Price | $54.80 | $112.79 |
| Today | −0.2% | +0.0% |
| Return YTD | −7.6% | +14.2% |
| Return 1Y | +0.4% | +32.1% |
| Since June 26, 2026 | −7.1% | −0.8% |
| P/E | 144.9 | 14.2 |
| P/S | 3.1 | 3.9 |
| P/B | 1.7 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More BMRN & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.